The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 2, 2010, Pages 249-257

  Lazǎr, Daniela ^a   Tǎban, Sorina ^a   Sporea, I ^a   Dema, Alis ^a   Cornianu, Mǎrmara ^a   Lazǎr, Elena ^a   Goldis A ^a   Rajţlia, Iulia ^a   Vernic, C ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Clinicopathological factors; Gastric cancer; p53; Survival

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953035952     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Steele RJC, Thompson AM, Hall PA, Lane DP, The p53 tumour suppressor gene, Br J Surg, 1998, 85(11):1460-1467.
2. van Oijen MG, Slootweg PJ, Gain-of-function mutations in the tumor suppressor gene p53, Clin Cancer Res, 2000, 6(6):2138-2145.
3. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K, The p53 gene is a potent determinant of chemosensitivity and radiosensivity in gastric and colorectal cancers, J Cancer Res Clin Oncol, 1996, 122(6):360-365.
4. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, Sugimachi K, Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma, Cancer, 1999, 85(2):302-308.
5. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K, Prognostic value of p53 protein expression for patients with gastric cancer - a multi-variate analysis, Br J Cancer, 1999, 79(7-8):1255-1261.
6. Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E, P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type, Ann Surg Oncol, 1999, 6(8):739-745.
7. Lee WJ, Shun CT, Hong RL, Wu MS, Chang CJ, Chen KM, Overexpression of p53 predicts shorter survival in diffuse type gastric cancer, Br J Surg, 1998, 85(8):1138-1142.
8. Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak SG, Gulten M, Memik F, Expression of p53 protein and prognosis in gastric carcinoma, J Int Med Res, 1999, 27(2):85-89.
9. Mcculloch P, Taggart T, Ochiai A, O'Dowd G, Nash J, Sasako M, c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan, Eur J Surg Oncol, 1997, 23(4):304-309.
10. Hosaka N, Ichikawa T, Ishikawa T, Nagashima Y, Kunisaki C, Takahashi M, Moriwaki Y, Akiyama H, Yamaguchi S, Ota M, Ooki S, Ike H, Shimada H, Correlation of immunohistochemical p53 labeling index with inhibition rate in chemosensivity test in gastric and colon cancer, Anticancer Res, 2001, 21(1A):229-235.
11. Itaya M, Yoshimoto J, Kojima K, Futagawa S, Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors, Oncol Rep, 1999, 6(3):675-682.
12. Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y, p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer, Anticancer Res, 2001, 21(3C):2149-2153.
13. Pinto-de-Sousa J, Silva F, David L, Leitão D, Seixas M, Pimenta A, Cardoso-de-Oliveira M, Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma, Histopathology, 2004, 44(4):323-331.
14. Lacueva FJ, Calpena R, Medrano J, Teruel A, Mayol MJ, Graells ML, Camarasa MV, Perez-Vazquez MT, Ferragut JA, Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53, Cancer, 2000, 89(1):21-28.
15. Lim BH, Soong R, Grieu F, Robbins PD, House AK, Iacopetta BJ, p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma, Int J Cancer, 1996, 69(3):200-204.
16. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T, p21 expression is a prognostic factor in patients with p53-negative gastric cancer, Cancer Lett, 2000, 148(2):181-188.
17. Ismail HM, Moneer M, El-Baradie M, Khorshid O, Touny A, Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray, J Egypt Natl Cancer Inst, 2007, 19(2):147-157.
18. Baldus SE, Schneider PM, Mönig SP, Zirbes TK, Fromm S, Meyer W, Glossmann J, Schuler S, Thiele J, Holscher AH, Dienes HP, p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status, Scand J Gastroenterol, 2001, 36(9):975-980.
19. Diez M, Medrano MJ, Gutierez A, López A, Muguerza JM, Hernandez P, Lozano O, Noguerales F, RuIz A, Granell J, P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy, Anticancer Res, 2000, 20(5C):3929-3933.
20. Kaye PV, Radebold K, Isaacs S, Dent DM, Expression of p53 and p21 waf1/cip1 in gastric carcinoma: lack of interrelationship or correlation with prognosis, Eur J Surg Oncol, 2000, 26(1):39-43.
21. Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, Sasaki K, Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma, Pathol int, 2001, 51(6):440-444.
22. Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M, Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer, Oncology, 1998, 55(6):594-599.
23. Ogawa M, Onoda N, Maeda K, Kato Y, Nakata B, Kang SM, Sowa M, Hirakawa K, A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis, int J Mol Med, 2001, 7(5):479-483.
24. Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ, Mutations of p53 gene in gastric carcinoma in Taiwan, Anticancer Res, 2001, 21(1B):513-520.
25. Ji F, Jin X, Jiao CH, Xu QW, Wang ZW, Chen YL, FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging, World J Gastroenterol, 2009, 15(18):2228-2233.
26. Honda T, Tamura G, Endoh Y, Nishizuka S, Kawata S, Motoyama T, Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentia-ted carcinoma of the stomach, Jpn J Clin Oncol, 2005, 35(10):580-586.
27. Yi SY, Lee WJ, A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer, world J Gastroenterol, 2006, 12(40):6536-6539.
28. Tang H, Hokita S, Che X, Baba M, Aridome K, Kijima F, Tanabe G, Takao S, Aikou T, Comparison of p53 expression in proximal and distal gastric cancer: histopa-thologic correlation and prognostic significance, Ann Surg Oncol, 1997, 4(6):470-474.
29. Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A, C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma, int J Surg Pathol, 2002, 10(4):247-256.
30. Pinto-de-Sousa J, David L, Seixas M, Pimenta A, Clinico-pathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum, Dig Surg, 2001, 18(2):102-110.
31. Siewert JR, Böttcher K, Stein HJ, Roder JD, Busch R, Problem of proximal third gastric carcinoma, World J Surg, 1995, 19(4):523-531.
32. Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Tatsumi M, Fujimoto H, Emoto K, Nakano H, Characteristics and clinical outcome of proximal-third gastric cancer, J Am Coll Surg, 1998, 187(4):352-357.
33. Azarhoush R, Keshtkar AA, Amiriani T, Kazemi-nejad V, Relationship between p53 expression and gastric cancers in cardia andantrum, Arch iran Med, 2008, 11(5):502-506.
34. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E, p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type, Cancer Epidemiol Biomarkers Prev, 1995, 4(3):223-231.
35. Vollmers HP, Dämmrich J, Hensel F, Ribbert H, Meyer-Bahlburg A, ufken-Gaul T, von Korff M, Muller-Hermelink HK, Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma, Cancer, 1997, 79(3):433-440.
36. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR, Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma, BMC Gastroenterol, 2009, 9:55.
37. Bong JG, Lee MH, Song KE, Kim T, Yu W, p53 gene mutation, tumor p53 protein overexpression, and serum anti-p53 antibody in patients with gastric cancer, J Korean Gastric Cancer Assoc, 2003, 3(4):206-213.
38. Zhang LL, Yu D, Xiong SB, Lang A, Ellis LM, Pollock RE, Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression, Cancer Res, 2000, 60(13):3655-3661.
39. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ, Clinico-pathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer, BMC Cancer, 2008, 8:123.
40. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N, Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma, Oncology, 1999, 57(2):164-172.
41. Sakatani T, Okamoto E, Tsujitani S, Ikeguchi M, Kaibara N, Ito H, Expression of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma, Oncol Rep, 2000, 7(4):831-836.
42. Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N, Nuclear accumulation of p53 protein in gastric cancer strongly correlated with enlargement of nuclear area of cancer cells, Oncol Rep, 2000, 7(3):579-584.
43. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ, Comparative study of tumor angiogenesis and immuno-histochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer, Histol Histopathol, 2000, 15(2):455-462.
44. Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni JF Jr, Rice JM, Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers, Cancer Epidemiol Biomarkers Prev, 2000, 9(6):631-633.
45. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP, Pronostic significance of Bcl-2 and p53 expression in gastric cancer, Int J Colorectal Dis, 2003, 18(6):518-525.
46. Starzyńska T, Małwniczak M, Marlicz K, Chosia M, Domagalstrok;a W, p53 protein in primary gastric carcinoma and coexisting metastases, Pol Merkur Lekarski, 2003, 15(86):125-128.
47. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K, Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma, Surgery, 2000, 128(3):408-416.
48. Song KY, Jung CK, Park WS, Park CH, Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma, Jpn J Clin Oncol, 2009, 39(5):290-296.
49. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H, The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinoma, Cancer, 1999, 85(9):1894-1902.
50. Danesi DT, Spanò M, Fabiano A, Altavista P, Pasqualetti P, Toscano MG, Antonini F, Catalano P, Mecozzi A, Picconi A, Daffinà A, Cucchiara G, Flow cytometric DNA ploidy, p53, PCNA and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients, Cytometry, 2000, 42(1):27-34.
51. Kim DH, Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer, Yonsei Med J, 2007, 48(4):694-700.
52. Kimura H, Konishi K, Kaji M, Maeda K, Yabushita K, Tsuji M, Ogino H, Satomura Y, Unoura M, Miwa A, Apoptosis, cell proliferation and expression of oncogenes in gastric carcinomas induced by preoperative administration of 5-fluorouracil, Oncol Rep, 2000, 7(5):971-976.
53. Ozgüroglu M, Demir G, Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma, Cancer, 1999, 86(3):547-549.
54. Yukimoto K, Nakata B, Muguruma K, Yashiro M, Ohira M, Ishikawa T, Hino M, Hirakawa K, Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation, Int J Oncol, 2001, 19(2):373-378.